Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-546-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.56 billion
Profitability
Miscellaneous
Employees23,300
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb declared a quarterly dividend on Wednesday, September 11th. Investors of record on Friday, October 4th will be given a dividend of $0.41 per share on Friday, November 1st. This represents a $1.64 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date of this dividend is Thursday, October 3rd. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings results on Thursday, July, 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.06 by $0.12. The biopharmaceutical company had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The company's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned $1.01 EPS. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
How can I listen to Bristol-Myers Squibb's earnings call?
Bristol-Myers Squibb will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $4.20-4.30 for the period, compared to the Thomson Reuters consensus estimate of $4.16.
What price target have analysts set for BMY?
14 brokers have issued 1 year target prices for Bristol-Myers Squibb's stock. Their forecasts range from $46.36 to $66.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $56.86 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb.
What is the consensus analysts' recommendation for Bristol-Myers Squibb?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.
Has Bristol-Myers Squibb been receiving favorable news coverage?
Press coverage about BMY stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a news impact score of 1.8 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Bristol-Myers Squibb.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Bristol-Myers Squibb own?
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 54)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
- Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
- Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
- Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhumbline Advisers (0.17%), Candriam Luxembourg S.C.A. (0.16%), PGGM Investments (0.16%), Douglas Lane & Associates LLC (0.08%), State of New Jersey Common Pension Fund D (0.08%) and Alberta Investment Management Corp (0.08%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Karen Murphy Santiago, Robert J Bertolini, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which institutional investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Envestnet Asset Management Inc., DNB Asset Management AS, State of Alaska Department of Revenue, Alberta Investment Management Corp, Varma Mutual Pension Insurance Co, Gateway Investment Advisers LLC and Decatur Capital Management Inc.. View Insider Buying and Selling for Bristol-Myers Squibb.
Which institutional investors are buying Bristol-Myers Squibb stock?
BMY stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Berkshire Asset Management LLC PA, Commerzbank Aktiengesellschaft FI, Candriam Luxembourg S.C.A., TIAA FSB, Artemis Investment Management LLP, Cullinan Associates Inc. and Rhenman & Partners Asset Management AB. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $54.77.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $89.59 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.View Additional Information About Bristol-Myers Squibb.
What is Bristol-Myers Squibb's official website?
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
